suppose we don't have MTAC Warfarin here (HTAA) but new update that i been told by madam rohani that we have MTAC Warfarin at HTAA on 15/10/2010 time 8.00-11.00 a.m.
and i think of course madam shahimi (correct me if wrong) would be the HTAA preceptor...
P/S: Students are requested to submit their reports to the relevant IIUM preceptor within ONE (1) week, i.e before the next scheduled attachment via drop box of e-learning portal (LMS).
The ACC/AHA recommendations are classified based on the benefit, risk, and level of evidence, with class I recommendations reflecting the highest benefit-to-risk ratio. The 2007 ACC/AHA class I recommendations for antiplatelet therapy in patients with NSTEMI or UA are listed in Table 1.
Immediate administration of a single 162- to 325-mg dose of non-enteric aspirin and addition of a 300- to 600-mg loading dose of the thienopyridine clopidogrel are recommended for all patients, regardless of whether an invasive or noninvasive strategy is chosen. Clopidogrel may be used instead of aspirin for patients who cannot take aspirin because of hypersensitivity or gastrointestinal (GI) intolerance. Patients with a history of GI bleeding should receive drugs to minimize the risk of recurrent GI bleeding (e.g., proton pump inhibitors) when receiving aspirin, clopidogrel, or both. Clopidogrel should be withheld for at least 5 days before elective CABG.
In patients with NSTEMI or UA for whom a conservative approach is chosen, it may be reasonable to add a platelet glycoprotein (GP) IIb/IIIa inhibitor (eptifibatide or tirofiban) to aspirin and clopidogrel, especially in patients with recurrent ischemic discomfort with clopidogrel, aspirin, and anticoagulants. However, the GP IIb/IIIa inhibitor abciximab should be avoided in these patients.
Guidelines for Antithrombotic Therapy in the Management of Acute Coronary Syndrome and Venous Thromboembolism in Health Systems by American Society of Health-System Pharmacists (ASHP) - http://ashpmedia.org/symposia/cvseries/ACS_DiscGuide_2.pdf
Berikut adalah grouping untuk OTC visit. Pada sesiapa yang ada PBL atau apa-apa hal lain yang tak boleh dielakkan pada tarikh yang ditetapkan, sila contact Mardhiyyah dan bagitau reason yang valid by tomorrow sebab hari rabu nak bagi list nama kat madam. sebar2kan pada semua..
Group 1:
Saif
Saifuddin
Islah
Salwani
Helmi Rahmat
Razak
Faiz Salleh
Helmi Azman
Ruzmayuddin
Lutfi
Hasbullah
Nik Ezmiza
Baizura
Atiqah
Shafiqa Alias
Group 2:
muhaimin
che am
zarif
ramdani
nusaibah
qayyum
amal S
shamil
huda
faris hanif aidasyafinaumiera
IIUM Pharmacy Sdn Bhd established in 2003, was integrated universal healthcare company in Malaysia. We will be opening our first commercial plant by the year end 2009. The plant is located at our International Islamic University Malaysia Campus in Kuantan, Pahang.
We will be the first Pharmaceutical Manufacturing Plant to produce syariah compliance plant firstly in Malaysia.
With staff strength of 35 initially, the plant shall be producing its first batch of GENERIC Drugs for commercialization by early next year. The 4 generic drugs are:
Mefenamia Acid 250mg
Cetrizine 10mg
Amlodipine 5mg
Gliclazide 80mg
As a commercial pharmaceutical plant closely associated with the Kulliyyah of Pharmacy IIUM, Kuantan, we are looking into the sector for cottage industry extract commercialization. The plant is currently working on with a few existing pharmacy plant on contract manufacturing and the possibility of our plant being use for Product testing.
Our commitment to inspiring people healthiness is guided by our philosophy of doing business with ethics; a philosophy we will continue to nurture as we journey towards becoming a global total integrated healthcare solutions provider.
